DUCHENNE –Results demonstrate continued safety and tolerability of SRP-9001 in four participants with Duchenne — –All four participants demonstrated improvements in NSAA scores compared to baseline and showed a durable response two years after administration of SRP-9001 — CAMBRIDGE, MA, USA I September 28, 2020 I Sarepta Therapeutics, Inc. (NASDAQ: […]